UNSPSC 51282942: Rosoxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Y1OT3J4NW, chemically known as 3-quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- but generally known as rosoxacin, which bears US NIH Compound Identifier 287180. European Medicines Agency schedules Rosoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10389MIG.

UNSPSC 51282942 Rosoxacin, a Commodity code, sees limited recent state and local activity tied directly to this specific pharmaceutical product. The two most recent state and local opportunities in the source are tagged to this code but do not involve rosoxacin procurement; instead, they cover other pharmaceutical products and harm-reduction supplies. The Illinois Department of Public Health awarded a piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, totaling $2.999 million over 12 months with two optional renewal years. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with a response deadline of July 26, 2026, requiring quarterly deliveries and vendor responsibility for all shipping costs. Neither opportunity involves rosoxacin directly.

The code's representation in recent state and local solicitations suggests minimal current demand specifically for rosoxacin. Activity under this code appears concentrated among health departments and county health agencies using cooperative purchasing vehicles and piggyback arrangements, but actual rosoxacin procurement is not evident in the recent record. Geographic spread is limited to Illinois and Florida in the available data. Firms pursuing this code should monitor state pharmacy and health-department sourcing cycles, but current pipeline activity is better characterized by antibiotics and emergency-response pharmaceuticals than by rosoxacin specifically.